Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

NCT04604691 · clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Seoul National University Hospital

Collaborators